Articles related to BREAST CANCER

The imminent CMS coding changes, leading to massive pay cuts, threaten to significantly reduce the availability of DIEP flap breast reconstruction, a procedure renowned for its superior patient outcomes. The potential repercussions, such as increased health disparities and a loss of specialized surgical skills, underscore the urgent need for policy reconsideration.

Explore this extensive study that highlights the recent major advancements in the prognosis for women with early invasive breast cancer while also emphasizing the impact of personal factors on mortality risk.

Unveiling USPSTF’s New Recommendation for Breast Cancer Screenings The US Preventive Services Task Force (USPSTF) has issued a notable change in breast cancer screening guidelines, shedding light on the growing concern of breast cancer morbidity in the United States. This recommendation has profound implications for early detection and potential reduction in mortality rates.

Pfizer is lagging behind its peers with Ibrance, but the pharma giant is attempting to unveil the potential of CDK2 inhibitors to overcome CDK4/6 resistance. At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Pfizer and Blueprint gave presentations on posters about their respective agents, and Incyte, Cyclacel, and a few private biotechs also had clinical trials going on. Although there are some positive signs, the research is still in its very early stages, and it is not apparent whether CDK2 inhibition is a workable monotherapy method.

Learn about the precise genomic tests and compassionate treatments one doctor is using to address racial inequities in breast cancer care. JAMA’s latest study highlights a discrepancy in breast cancer care for Black women. The accuracy of widely used genomic tests for breast cancer, such as Oncotype DX, is notably less reliable for Black women. Hence, there’s an urgent call to address racial disparities in breast cancer care, especially as Black women currently face 41% higher mortality rates than white women. Dr. Nathalie Johnson, President of The American Society of Breast Cancer Surgeons, advocates for Agendia’s tests, which focus solely on biological factors. Such tests disregard race, ethnicity, age, or menopausal status, allowing for truly personalized treatment selection. Moreover, understanding every woman’s unique cancer empowers not only the patients but also their care teams. Recent research confirms that Black women are more likely to experience high-risk recurrence and death from axillary node-negative breast cancer compared to their non-Hispanic white counterparts. It reveals that Oncotype DX tests have lower prognostic accuracy for Black women. It points to the need for model calibration in genomic assays for populations with more racial/ethnic diversity. Dr. Johnson emphasizes personalized medicine and stresses the importance of […]

ASCO 2023 abstracts: a glimpse into groundbreaking advancements in the oncology field. At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Gilead Sciences and Kite Oncology are set to present 30 abstracts. Their data underscores their leadership in hard-to-treat cancers, notably metastatic breast cancer. In addition, they highlight a growing presence in lung cancer and other tumor types. Trodelvy® (sacituzumab govitecan-hziy) emerges as a promising treatment for HR+/HER2- metastatic breast cancer (mBC) with the final overall survival (OS) results from the Phase 3 TROPiCS-02 study. Its efficacy extends to metastatic urothelial cancer (UC) and advanced endometrial cancer, reinforcing its pan-tumor potential. Moreover, Yescarta® (axicabtagene ciloleucel) offers a ray of hope for adult patients with relapsed/refractory large B-cell lymphoma (LBCL). Notably, this CAR T-cell therapy demonstrates a statistical improvement over standard care in overall survival, marking a significant medical breakthrough. Gilead’s oncology pipeline, particularly for lung cancer, is expanding. The ongoing late-stage development program evaluates Trodelvy in non-small cell lung cancer (NSCLC). Also, the updated interim analysis of ARC-7, evaluating domvanalimab in first-line NSCLC, will be presented. Presentations at ASCO 2023 will also share trial updates from ongoing studies in lung cancer, triple-negative breast cancer, UC, and other solid […]